Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.56 USD
Change Today -0.41 / -2.42%
Volume 10.1M
BSX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 4:15 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

300 Boston Scientific Way

Marlborough, MA 01752

United States

Phone: 508-683-4000

Fax:

a Food and Drug Administration, and the U.S. FDA approval; and is the first device-based asthma treatment approved by the FDA. Urology and Women’s Health The company’s Urology and Women’s Health business develops, manufactures, and sells devices to treat various urological and gynecological disorders. Within its Urology business, the company sells various products designed to treat patients with urinary stone disease and benign prostatic hyperplasia. The company offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons, and catheters. Within the company’s Women's Health business, it markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), menorrhagia (excessive menstrual bleeding), and uterine fibroids and polyps. The company offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. The company markets its Genesys Hydro ThermAblator system, an ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. In the U.S., the company is in the process of launching the Symphion System for the removal of intrauterine fibroids and polyps. Neuromodulation Within the company’s Neuromodulation business, it markets the Precision and Precision Spectra Spinal Cord Stimulator (SCS) systems, used for the management of chronic pain. These systems manage chronic pain by applying an electrical signal to mask pain signals traveling from the spinal cord to the brain. The company’s major portfolio includes the CoverEdge family of 32-contact surgical leads, with various contacts than any other marketed lead; the Infinion 16 Percutaneous Lead; the 16-contact percutaneous lead; and its Linear 3-4 and Linear 3-6 Percutaneous Leads. These leads are for use with the company’s 2- and 4-port SCS pulse generators, and provide the range of configurations in the industry, engineered to provide more pain relief to a spectrum of patients. The Precision Spectra SCS System is a SCS system with 32 contacts and 32 power sources and is designed to provide improved pain relief to a range of patients who suffer from chronic pain. The company is conducting two large scale prospective clinical trials exploring stimulation with multiple new waveforms, based on the Precision and Precision Spectra platforms, such as its ACCELERATE study evaluating high-rate (10kHz) stimulation, and the WHISPER study exploring a proprietary sub-perception stimulation waveform. Marketing and Sales During 2014, the company marketed its products to approximately 25,000 hospitals, clinics, outpatient facilities, and medical offices in the U.S. and across approximately 110 countries worldwide. The company also has a network of distributors and dealers who offer its products in certain countries and markets. Business Strategy The company’s five strategic imperatives include strengthen execution to improve share; expanding into high growth adjacencies; driving global expansion; funding the journey to fuel growth; and developing key capabilities. Research and Development The company expended $817 million on research and development in 2014. Proprietary Rights As of December 31, 2014, the company held approximately 16,000 patents and had approximately 6,200 patent applications pending worldwide that cover various aspects of its technology. Seasonality The company’s worldwide sales do not reflect any significant degree of seasonality, however, customer purchases have historically been lower in the third quarter of the year (year ending December 2014), as compared to other quarters. This reflects, among other factors, lower demand during summer months in the northern hemisphere, particularly in European countries. Competition The company’s primary competitors include Abbott Laboratories; Medtronic, Inc.; St. Jude Medical, Inc.; Cook Medical Inc.; and others. History Boston Scientific Corporation was fou

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $16.56 USD -0.41

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥2,027 JPY +27.00
Coloplast A/S kr530.50 DKK +4.00
Olympus Corp ¥4,415 JPY +240.00
St Jude Medical Inc $66.53 USD -1.20
Terumo Corp ¥3,255 JPY +10.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 3.5x
Price/Cash Flow 70.0x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.